期刊文献+

黏膜切除治疗Barrett食管疗效及安全性的Meta分析

Meta-analysis of effect and safety of endoscopic mucosal resection in treating Barrett esophagus
下载PDF
导出
摘要 目的评价黏膜切除(EMR)对于Barrett食管(BE)治疗的有效性、持久性及不良事件发生率。方法计算机检索Embase、PubMed、维普、中国期刊全文数据库、万方数字化期刊全文数据库等。提取各病理类型的BE接受EMR治疗后根除肠上皮化生(CE-IM)、上皮内瘤变(CE-N)的比率,治疗随访期间肠上皮化(IM)或瘤变复发及不良事件发生率,应用R3.1.3软件合并数据进行统计学分析,计算其有效性、持久性及不良事件发生率。结果共纳入4篇研究,总病例130例。EMR治疗异型增生或黏膜内癌的BE患者中,达到CE-N为97%(95%CI:0.91~0.99),达到CE-IM为91%(95%CI:0.83~0.95),在随访过程中瘤变或IM复发率为8%,常见并发症食管狭窄与出血,其发生率分别为39%和6%。结论 EMR作为BE内镜治疗的推荐方式,其在治疗伴异型增生或黏膜内癌的BE上有确切的效果,但其并发症特别是食管狭窄发生率较高。 Objective To evaluate the effectiveness,persistence and incidence of adverse events of endoscopic mucosal resection(EMR)for the treatment of Barrett esophagus(BE).Methods The full-tex databases of Embase,PubMed,VIP,CNKI,Wanfang database were retrieved by computer.The proportion of eradication of intestinal metaplasia(CE-IM)and neoplasia(CE-N),recurrence of intestinal metaplasia(IM)and adenocarcinoma,and adverse events occurred during the follow-up after receiving ENR in different pathological types of BE were extracted.The extracted data were pooled and statistically analyzed by using the R3.1.3software.Results 4researches were included,involving130 patients.In the patients with high grade dysplasia(HGD)or intramucosal carcinoma treated by EMR,reached CE-N was 97%(95%CI:0.91-0.99),reached CE-IM was 91%(95%CI:0.87-0.94),neoplasia or IM recurrence rate was 8%,the esophageal stricture and bleeding were common,their incidence rates were 39% and 6%respectively.Conclusion EMR as the recommend mode for BE endoscopic therapy has definite effect in treating BE complicating dysplasia or intramucosal carcinoma,but has the higher occurrence rate of complications,especially esophageal stricture.
出处 《检验医学与临床》 CAS 2016年第7期870-872,共3页 Laboratory Medicine and Clinic
基金 国家自然科学基金资助项目(81070318) 重庆市科委基金资助项目(渝科发[2002]18-86号) 重庆市教委基金资助项目(渝教科[2002]18-6号)
关键词 BARRETT食管 食管黏膜切除 META分析 Barrett esophagus esophageal mucosal resection Meta-analysis
  • 相关文献

参考文献2

二级参考文献36

  • 1[1]Blot WJ,Devesa SS,Kneller RW,Fraumeni JF Jr.Rising incidence of adenocarcinoma of the esophagus and gastric cardia.JAMA 1991; 265:1287-1289
  • 2[2]Bollschweiler E,Wolfgarten E,Gutschow C,Holscher AH.Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.Cancer 2001; 92:549-555
  • 3[3]Conio M,Lapertosa G,Bianchi S,Filiberti R.Barrett's esophagus:an update.Crit Rev Oncol Hematol 2003; 46:187-206
  • 4[4]Conio M,Blanchi S,Lapertosa G,Ferraris R,Sablich R,Marchi S,D'Onofrio V,Lacchin T,Iaquinto G,Missale G,Ravelli P,Cestari R,Benedetti G,Macri G,Fiocca R,Munizzi F,Filiberti R.Long-term endoscopic surveillance of patients with Barrett's esophagus.Incidence of dysplasia and adenocarcinoma:a prospective study.Am J Gastroenterol 2003; 98:1931-1939
  • 5[5]Shaheen NJ,Crosby MA,Bozymski EM,Sandler RS.Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119:333-338
  • 6[6]Reid BJ,Levine DS,Longton G,Blount PL,Rabinovitch PS.Predictors of progression to cancer in Barrett's esophagus:baseline histology and flow cytometry identify low-and highrisk patient subsets.Am J Gastroenterol 2000; 95:1669-1676
  • 7[7]Schnell TG,Sontag SJ,Chejfec G,Aranha G,Metz A,O'Connell S,Seidel UJ,Sonnenberg A.Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.Gastroenterology 2001; 120:1607-1619
  • 8[8]Weston AP,Sharma P,Topalovski M,Richards R,Cherian R,Dixon A.Long-term follow-up of Barrett's high-grade dysplasia.Am J Gastroenterol 2000; 95:1888-1893
  • 9[9]Cameron AJ,Carpenter HA.Barrett's esophagus,high-grade dysplasia and early adenocarcinoma:a pathologic study.Am J Gastroenterol 1997; 92:586-591
  • 10[10]Korst RJ,Altorki NK.High-grade dysplasia:surveillance,mucosal ablation,or resection? World J Surg 2003; 27:1030-1034

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部